2024-11-20 10:22:17
CStone announces China's NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC
Corporate/ 2023-07-23
CStone announces China's NMPA has a...

Sugemalimab becomes the world\'s first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival (PFS) in patie...

Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2022
Corporate/ 2023-07-23
Global Cord Blood Corporation Reports Fi...

1Q22 Added 19,673 New Subscribers Revenues Up 12.2% YoY to RMB315.2 Million ($48.8 Million) Gross Profit Up 12.6% YoY to RMB267.3 Million ...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release